Waters (WAT) is down about 3.35% to roughly $290 as investors react to a weaker-than-expected first-quarter 2026 earnings outlook. The company projected Q1 2026 non-GAAP EPS of $2.25 to $2.35, a range that has been treated as a disappointment versus Street expectations and is pressuring the stock despite solid recent results. (investing.com)

For Q1 2026, Waters expects total company revenue of $1.198 billion to $1.211 billion, including about $480 million from the acquired business on an owned-period basis. For full-year 2026, Waters guided to total reported revenue of $6.405 billion to $6.455 billion and non-GAAP EPS of $14.30 to $14.50, numbers that frame the debate over whether near-term earnings power will keep up with the expanded cost base and financing needs. (ir.waters.com)

The market’s reaction reflects sensitivity to near-term profitability and execution as Waters absorbs a major portfolio expansion. With the BD Biosciences & Diagnostic Solutions combination closing in early 2026, traders are pricing in a wider band of outcomes around integration pace, synergy timing, and incremental costs, making quarterly EPS cadence more important than usual. (investing.com)

Next catalysts include any updates on early integration progress, synergy capture, and whether demand trends support the company’s organic growth assumptions. Investors will also focus on whether Waters can re-accelerate EPS growth after a subdued Q1 guide, and on any changes to full-year 2026 targets as the combined company reports through the year. (ir.waters.com)